Rapid reversal of no-reflow using Abciximab after coronary device intervention

Catheterization and Cardiovascular Diagnosis

Volumn 42, Issue 2, 1997, Pages 187-190

  Rawitscher, David ^a   Levin, Thomas N ^a   Cohen, Ian ^a   Feldman, Ted ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

No reflow; Platelet inhibitor; PTCA

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CREATINE KINASE MB; DILTIAZEM; GLYCERYL TRINITRATE; HEPARIN; ISOSORBIDE DINITRATE; LOSARTAN POTASSIUM; METOPROLOL TARTRATE; VERAPAMIL;

AGED; ANGIOCARDIOGRAPHY; ATHERECTOMY; BLOOD CLOT LYSIS; CASE REPORT; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DEVICE; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTRACORONARY INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; REVIEW; STENOSIS; SYNDROME; THROMBOCYTE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ATHERECTOMY, CORONARY; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY CIRCULATION; CORONARY VASOSPASM; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MYOCARDIAL REPERFUSION INJURY; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; STENTS;

EID: 0030763316     PISSN: 00986569     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0304(199710)42:2<187::AID-CCD20>3.0.CO;2-K     Document Type: Review

References (14)

1. Kloner RA, Ganote CE, Jennings RB: The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 54:1496-1508, 1974.
2. Schofer J, Montz R, Mathey D: Scintigraphic evidence of the "no reflow" phenomenon in human beings after coronary thrombolysis. J Am Coll Cardiol 5:593-598, 1985.
3. Kenner MD, Zajac EJ, Kondos GT, Dave R, Winkelmann JW, Joftus J, Laucevicius A, Kybarskis A, Berukstis E, Urbonas A, Feinstein SB: Ability of the no-reflow phenomenon during an acute myocardial infarction to predict left ventricular dysfunction at one month follow-up. Am J Cardiol 76:861-867, 1995.
4. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T: Clinical implications of the 'no reflow' phenomenon. Circulation 93:223-228, 1996.
5. Piana, RN, Piak GY, Moscucci M, Cohen DJ, Gibson CM: Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation 89:2514-2518, 1994.
6. Kitazume H, Iwama T, Kubo I, Ageishi Y, Suzuki A: No-reflow phenomenon during percutaneous transluminal coronary angioplasty. Am Heart J 116:211-215, 1988.
7. Feld H, Lichstien E, Schachter J, Shani J: Early and late angiographie findings of the "no-reflow" phenomenon following direct angioplasty as the primary treatment for acute myocardial infarction. Am Heart J 123:782-784, 1992.
8. Komamura K, Kitakaze M, Nishida K, Naka M, Tamai J, Uematsu M, Koretsune Y, Nanto S, Hori M, Inoue M, Kamada T, Kodama K: Progressive decrease in coronary vein flow during reperfusion in acute myocardial infarction: Clinical documentation of the no reflow phenomenon after successful thrombolysis. J Am Coll Cardiol 24:370-377, 1994.
9. Seydoux C, Goy J, Graham D: Platelet and neutrophil imaging techniques in the investigation of the response to thrombolytic therapy and the no-reflow phenomenon. Am Heart J 125:1142-1147, 1993.
10. Mehta JL, Nichols WW, Mehta P: Neutrophils as potential participants in acute myocardial ischemia: relevance to reperfusion. J Am Coll Cardiol 11:1309-1316, 1988.
11. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 330:956-961, 1994.
12. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators: Randomized trial of coronary intervention with antibody against platelet Iib/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC investigators. Lancet 343:881-886, 1994.
13. Topol EJ: Evaluation of PTCA to improve long-term outcomes by c7E3 glycoprotein IIb/IIa receptor blockade (EPILOG). Presented at the Scientific Session of the European Society of Cardiology, Birmingham, England, August 27, 1996.
14. Ferguson JJ: EPILOG and CAPTURE trials halted because of positive 3 interim results. Circulation 93:637, 1996.